MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+8.89%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$385M
AUM Growth
+$385M
(-8.7%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-2.97%
Top 10 Holdings %
Top 10 Hldgs %
72.83%
Holding
43
New
5
Increased
16
Reduced
4
Closed
10
Top Buys
| 1 |
uniQure
QURE
|
$21.3M |
| 2 |
Insmed
INSM
|
$8.2M |
| 3 |
Axsome Therapeutics
AXSM
|
$4.01M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$3.35M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$2.87M |
Top Sells
| 1 |
Merus
MRUS
|
$18.4M |
| 2 |
Cytokinetics
CYTK
|
$9.36M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$7.63M |
| 4 |
Y-mAbs Therapeutics
YMAB
|
$6.4M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$5.22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $80.7M | 20.93% | 7,648,268 | – | – |
|
2
iTeos Therapeutics
ITOS
| $34.1M | 8.85% | 1,745,943 | – | – |
|
|
INBX
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $31.7M | 8.22% | 1,286,435 +6,440 | +0.5% | +$159K |
|
4
Repare Therapeutics
RPTX
$71.7M
| $24.1M | 6.26% | 1,639,849 | – | – |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $22.7M | 5.89% | 1,059,688 +9,688 | +0.9% | +$207K |
|
|
6
uniQure
QURE
$896M
| $21.3M | 5.53% | +939,966 | New | +$21.3M |
|
7
Geron
GERN
$893M
| $20.5M | 5.32% | 8,466,981 +44,399 | +0.5% | +$107K |
|
8
Intellia Therapeutics
NTLA
$1.22B
| $15.9M | 4.12% | 455,238 +80,829 | +22% | +$2.82M |
|
|
VERV
9
DELISTED
Verve Therapeutics
VERV
| $15.6M | 4.06% | 808,661 +172,869 | +27% | +$3.35M |
|
10
Regenxbio
RGNX
$451M
| $14.1M | 3.66% | 621,372 +2,289 | +0.4% | +$51.9K |
|
|
11
Iovance Biotherapeutics
IOVA
$807M
| $13.7M | 3.56% | 2,149,550 +449,550 | +26% | +$2.87M |
|
|
PRVB
12
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $9.5M | 2.46% | 898,483 +158,139 | +21% | +$1.67M |
|
|
13
Insmed
INSM
$28.8B
| $8.2M | 2.13% | +410,463 | New | +$8.2M |
|
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.77M | 2.02% | 26,773 -17,974 | -40% | -$5.22M |
|
15
Harmony Biosciences
HRMY
$2.12B
| $7.68M | 1.99% | 139,377 +2,597 | +2% | +$143K |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $7.38M | 1.91% | 194,181 +15,123 | +8% | +$575K |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.8M | 1.76% | 371,639 +6,929 | +2% | +$127K |
|
18
Travere Therapeutics
TVTX
$1.56B
| $5.92M | 1.54% | 281,711 +5,251 | +2% | +$110K |
|
19
Werewolf Therapeutics
HOWL
$59.9M
| $4.9M | 1.27% | 2,388,011 | – | – |
|
20
Amicus Therapeutics
FOLD
$2.34B
| $4.89M | 1.27% | 400,410 +7,464 | +2% | +$91.1K |
|
|
21
Axsome Therapeutics
AXSM
$6.05B
| $4.01M | 1.04% | +51,975 | New | +$4.01M |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| $3.88M | 1.01% | 262,069 +4,884 | +2% | +$72.3K |
|
23
Revolution Medicines
RVMD
$7.1B
| $3.55M | 0.92% | 149,043 +3,002 | +2% | +$71.5K |
|
|
GTHX
24
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.53M | 0.92% | 650,000 -206,798 | -24% | -$1.12M |
|
|
TCRR
25
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.37M | 0.87% | 3,370,982 | – | – |
|